Effects of dopaminomimetics on the secretion of VIP-like immunoreactivity in conscious dogs.
The effects of some dopaminomimetics on VIP levels in peripheral venous blood of conscious dogs were analysed with a radioimmunoassay. The dopamine D2 agonist pergolide, like apomorphine and bromocriptine, increased VIP levels. The putative DA autoreceptor agonist 3PPP, as well as the D1 agonist SK&F 38393 were devoid of action. The D1 antagonist SCH 23390 did not abolish the effect of apomorphine. It is suggested that monitoring of VIP levels could be an interesting screening test for activity at D2 receptors. Amphetamine did not modify VIP levels suggesting that DA neurons are not involved in the mechanism leading to a release of VIP. The VIP response to apomorphine was not suppressed by an infusion of somatostatin. Decreasing blood pressure with nitroglycerin or with the adrenergic antagonist prazosin did not release VIP. The mechanism by which administration of dopaminomimetics lead to a release of VIP is further discussed.
D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D000661:Amphetamine / Q000494:pharmacology; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001552:Benzazepines / Q000494:pharmacology; D004285:Dogs; D004873:Ergolines / Q000494:pharmacology*; D005996:Nitroglycerin / Q000494:pharmacology; D010479:Pergolide; D010880:Piperidines / Q000494:pharmacology; D011224:Prazosin / Q000494:pharmacology; D011954:Receptors, Dopamine / Q000187:drug effects* / Q000502:physiology; D013004:Somatostatin / Q000494:pharmacology; D014660:Vasoactive Intestinal Peptide / Q000378:metabolism*
D001552:Benzazepines; D004873:Ergolines; D010880:Piperidines; D011954:Receptors, Dopamine; D010479:Pergolide; D014660:Vasoactive Intestinal Peptide; D013004:Somatostatin; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; C026539:preclamol; D000661:Amphetamine; D005996:Nitroglycerin; D001058:Apomorphine; D011224:Prazosin